Kovack Advisors Inc. Grows Position in Moderna, Inc. (NASDAQ:MRNA)

Kovack Advisors Inc. lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 207.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 5,844 shares of the company’s stock after purchasing an additional 3,946 shares during the quarter. Kovack Advisors Inc.’s holdings in Moderna were worth $391,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRNA. Cedar Wealth Management LLC lifted its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after buying an additional 93 shares in the last quarter. CVA Family Office LLC increased its holdings in shares of Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after purchasing an additional 96 shares during the period. Claro Advisors LLC increased its stake in Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after buying an additional 108 shares during the period. Finally, McAdam LLC increased its stake in shares of Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after acquiring an additional 117 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 2,930 shares of company stock worth $217,170. Insiders own 15.70% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $39.77 on Friday. The firm’s 50 day simple moving average is $59.96 and its 200 day simple moving average is $97.80. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 1-year low of $38.76 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the company posted ($1.39) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -9.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on MRNA. The Goldman Sachs Group dropped their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Jefferies Financial Group lowered their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research note on Monday, November 4th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $93.18.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.